Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03489993 · ClinicalTrials.gov registry record
FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 8
- Enrollment target
NCT03489993 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 8 participants.
The verdict
NCT03489993 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
Study Summary
Hereditary hypophosphatemia encompasses rare genetic conditions characterized by renal phosphate wasting. Increased circulating levels of fibroblast growth factor 23 (FGF23), a key regulator of phosphorus metabolism, are critical to the pathophysiology of these diseases, most notably in X-linked hypophosphatemia (XLH). Increased FGF23 induces hypertrophy and scarring in the heart in part via stimulating the traditional renin-angiotensin system (RAS) pathway, angiotensin-converting enzyme (ACE)/angiotensin (Ang ll), particularly in patients with chronic kidney disease, but the effect of FGF23 on the heart in patients with FGF23-related hypophosphatemic diseases is unknown. In addition, the relationship between FGF23 and the angiotensin-converting enzyme 2 (ACE2)/angiotensin-(1-7) (Ang-(1-7) pathway of the RAS is unknown. The objective of this study is to describe the relationship between FGF23, which causes low phosphorus levels, and components of the RAS in the blood and urine to help the investigators understand why the disease occurs and how to better treat it. Subjects will be identified by querying the Electronic Medical Record according to medical diagnosis. Thirty subjects, 2-24 years of age, will be recruited from the tertiary care Pediatric Endocrinology and Pediatric Nephrology clinics at Brenner Children's Hospital. Inclusion criteria include a confirmed diagnosis of hereditary FGF23-related hypophosphatemia. Clinical data will be obtained from the Electronic Medical Record. Each subject will undergo study assessments at baseline, 6 months and 1 year that include blood work, an echocardiogram, and blood pressure measurements. The primary hypothesis is that subjects with higher Ang-(1-7) levels have lower rates of cardiac hypertrophy and thus are protected against high FGF23 levels. The secondary hypothesis is that subjects with higher Ang-(1-7) levels have lower systolic blood pressure.
Interventions
- DIAGNOSTIC_TEST Ang II and Ang-(1-7)
- DIAGNOSTIC_TEST FGF23 and klotho
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-12-06 |
| Est. Completion | 2020-12-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03489993
The ClinicalTrials.gov registry entry for NCT03489993 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ang II and Ang-(1-7) is the first listed.
NCT03489993 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03489993 about?
NCT03489993 is a clinical study titled "FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)". Hereditary hypophosphatemia encompasses rare genetic conditions characterized by renal phosphate wasting. Increased circulating levels of fibroblast growth factor 23 (FGF23), a key regulator of phosphorus metabolism, are critical to the pathophysiology of these diseases, most notably in X-linked hyp...
What is the current status of trial NCT03489993?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2018-12-06. Estimated completion is 2020-12-23.
What interventions are being tested in trial NCT03489993?
The interventions under investigation include: Ang II and Ang-(1-7) (DIAGNOSTIC_TEST), FGF23 and klotho (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03489993?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.